New Single-Dose flu drug for kids shows promise in trial

NCT ID NCT07357051

Recruiting now Symptom relief Sponsor: Joincare Pharmaceutical Group Industry Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new medicine called JKN2301 for children aged 2 to 11 with the flu. It is a single-dose treatment compared to the standard 5-day oseltamivir (Tamiflu) course. The goal is to see if it safely reduces flu symptoms and fever faster. About 177 children will take part to check safety and how well it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JKN2301 dry suspension
What this could lead to: If it works, this could offer a new single-dose treatment option for children with the flu, potentially easing symptoms faster.
What could go wrong: This is an early phase 3 trial with only 177 children, so results may not apply to all. The drug could cause side effects or not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLUENZA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

influenza viral respiratory tract infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RESPIRATORY VIRAL INFECTION

Contacts and locations

Locations

First Affiliated Hospital of Guangzhou Medical University
RECRUITING

Guangzhou, Guangdong, 510000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.